Omeprazole A2845: Research Workflow Guide

Omeprazole (SKU A2845) is supplied for experimental workflows examining proton pump inhibition and gastric acid biology. The product dossier identifies the compound as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, with a molecular formula of C17H19N3O3S and a molecular weight of 345.42 g/mol. In this article, the stated activity and handling values are treated as product-dossier information rather than newly generated or independently verified paper results. No directly matched publication evidence was supplied for this SKU.

For the current specification, review the Omeprazole product information before starting a study. The APExBIO material is intended strictly for scientific research use and should not be used for diagnosis, treatment, or human administration.

What This Product Solves

Many gastric acid secretion research workflows need a chemically defined inhibitor that can be introduced into a controlled assay and compared with vehicle-treated controls. A2845 addresses that need as an H+,K+-ATPase inhibitor for studies involving acid secretion mechanisms, proton pump inhibition, and antiulcer activity study designs. The dossier reports an IC50 of 5.8 µM for H+,K+-ATPase inhibition and an IC50 of 0.16 µM for histamine-induced acid formation. These values are useful as product-level reference points when planning assay ranges, but they should not be treated as universal potency constants across different species, preparations, readouts, incubation times, or buffer systems.

The compound is particularly relevant to gastric acid secretion research and controlled in vitro or ex vivo experiments. It may also serve as one component of a peptic ulcer disease model or a gastric acid-related disorders workflow when the model has a validated acid-secretion endpoint. The product dossier does not establish efficacy in a specific animal model, clinical setting, or disease population. Investigators should therefore define the biological model and endpoint independently rather than inferring disease-level outcomes from the inhibitor designation.

Because Omeprazole is insoluble in water and ethanol but has a stated DMSO solubility of at least 17.27 mg/mL, the main operational problem is not simply selecting an inhibitor; it is preparing a homogeneous, traceable stock and maintaining a consistent vehicle during dilution. A preparation that precipitates during transfer can produce an apparent loss of activity or high well-to-well variability.

Protocol Parameters

• Assay: H+,K+-ATPase inhibition; Value: IC50 5.8 µM; Applicability: product-level benchmark for proton pump inhibition assay planning; Rationale: provides a reference point for designing a concentration-response experiment without assuming that the same value will apply to every assay format; Source type: product specification.
• Assay: Histamine-induced acid formation; Value: IC50 0.16 µM; Applicability: benchmark for an acid-secretion readout involving histamine stimulation; Rationale: helps distinguish a secretion-based reference from the separate H+,K+-ATPase value; Source type: product specification.
• Identity: Omeprazole, 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide; Value: molecular weight 345.42 g/mol; Applicability: stock calculation, sample labeling, and analytical confirmation; Rationale: an explicit identity and molecular weight reduce transcription and molarity-conversion errors; Source type: product specification.
• Stock solvent: DMSO; Value: solubility ≥17.27 mg/mL; Applicability: preparation of a concentrated research stock; Rationale: the dossier reports insolubility in water and ethanol, so DMSO is the stated practical solvent for initial dissolution; Source type: product specification.
• Storage: solid material; Value: -20°C; Applicability: routine and long-term material storage; Rationale: the dossier recommends solid-state storage and does not recommend long-term storage of solution form; Source type: product specification.
• Quality attribute: chemical purity; Value: approximately 98%; Applicability: batch documentation and interpretation of assay-to-assay variation; Rationale: purity should be recorded with the lot and considered when comparing independent experiments; Source type: product specification.

Workflow Setup and QC Checklist

1. Confirm identity and receiving conditions

Record SKU A2845, lot information, receipt date, container condition, and the amount received. Small-molecule shipments require blue ice according to the dossier. If the container is compromised or the material appears altered, quarantine it until the responsible laboratory scientist reviews the issue. Confirm the label, chemical name, formula, and molecular weight against the study worksheet before weighing.

2. Store the solid correctly

Place the unopened or capped solid material at -20°C. Minimize unnecessary warming and repeated handling. Use a dedicated aliquoting plan if the container will be opened often. Do not prepare a large solution batch for long-term storage: the dossier specifically advises against long-term storage in solution form.

3. Prepare a traceable DMSO stock

Calculate the required mass from the intended molar stock concentration and the stated molecular weight of 345.42 g/mol. Dissolve the weighed solid in DMSO using a documented volume, mix until visually homogeneous, and record the preparation date, operator, solvent lot, concentration, and container identifier. Since water and ethanol are reported as unsuitable solvents for dissolution, do not substitute either without separate validation.

4. Control dilution and vehicle exposure

When transferring the stock into an aqueous assay matrix, add it gradually with consistent mixing and inspect the final preparation for haze or precipitate. Match the final DMSO content across all treatment and vehicle-control conditions. Establish the highest solvent percentage tolerated by the specific assay rather than assuming that a published or historical vehicle limit applies. If precipitation appears, pause interpretation, document the event, and repeat the dilution validation.

5. Build assay controls before testing samples

Include an untreated or stimulated control appropriate to the acid-secretion system, a DMSO vehicle control, and a positive control only if the laboratory has a validated reference material. For a histamine-induced acid formation experiment, define the unstimulated and histamine-stimulated conditions before adding the inhibitor series. Use technical replicates and predefine exclusion criteria for wells with visible precipitation, dispensing failure, or signal outside the instrument's validated range.

6. Document the analysis

Report the exact preparation concentration, dilution sequence, final vehicle percentage, exposure duration, assay matrix, temperature, readout method, and biological replicate structure. Fit concentration-response data only when the curve design and signal range support such an analysis. Report the observed estimate with its assay context; do not label the product-dossier IC50 values as results generated in the local experiment.

For a complementary stepwise discussion of preparation and acid-secretion experiments, see Omeprazole (A2845): Practical Protocols for Gastric Acid Research; it focuses on execution details that extend the parameter framework above.

The Omeprazole (A2845): Research Workflow Guide provides a related handling and application perspective for proton pump inhibition and antiulcer activity workflows.

Common Failure Modes and Fixes

Precipitation after aqueous dilution

Likely cause: the DMSO stock was diluted too rapidly, the final solvent fraction was too low for the compound load, or mixing was insufficient. Fix: validate the dilution sequence with the exact assay matrix, add stock incrementally, mix consistently, and inspect every preparation before dispensing. Do not interpret cloudy wells as a biological response without resolving the physical issue.

Unexpectedly weak or variable inhibition

Likely causes: inaccurate stock calculation, incomplete dissolution, unequal DMSO content, degraded solution, or use of a product benchmark outside its relevant assay context. Fix: recalculate from the stated molecular weight, verify visual homogeneity, use fresh working solutions when practical, include vehicle controls, and report assay-specific conditions alongside the result.

Loss of reproducibility between runs

Likely causes: repeated warming of the solid, untracked aliquots, inconsistent incubation timing, or changes in cell, tissue, enzyme, or buffer preparation. Fix: standardize the preparation worksheet, minimize freeze-thaw or warm-cool cycling, use the same order of addition, and record all variables that differ between runs.

Misinterpretation of the two IC50 values

The H+,K+-ATPase benchmark and the histamine-induced acid-formation benchmark describe different experimental contexts. They should not be substituted for one another, used to predict clinical dosing, or treated as proof of activity in a peptic ulcer disease model. Select the reference that most closely matches the assay endpoint and characterize the local response empirically.

Scope and Limitations

A2845 is a research reagent for controlled laboratory studies. The dossier supports its use in gastric acid secretion mechanisms, proton pump inhibition, antiulcer drug development, and related experimental workflows. It does not provide clinical efficacy, diagnostic performance, toxicology, pharmacokinetic exposure, or validated outcomes for patients with gastric acid-related disorders. It also does not establish that a given concentration will be effective in a particular cell line, tissue preparation, animal model, or instrument-based readout.

Solvent compatibility is a practical boundary: the material is reported as insoluble in water and ethanol, while DMSO provides the stated solubility of at least 17.27 mg/mL. Researchers should validate the final vehicle and dilution sequence in their own matrix. Purity of approximately 98% is a product-quality descriptor, not a substitute for assay controls, identity confirmation, or independent analytical testing when those controls are required.

Finally, no directly matched paper evidence was provided for this specific product record. Conclusions should therefore be limited to the supplied dossier values, the observed local assay data, and documented workflow performance. Avoid extending results to medical or diagnostic claims.

Conclusion

Omeprazole A2845 is most useful when treated as a controlled H+,K+-ATPase inhibitor with explicit preparation and storage constraints. Use the product-dossier IC50 values as planning benchmarks, prepare stocks in DMSO, protect the solid at -20°C, control vehicle exposure, and document precipitation or handling deviations. This approach supports reproducible gastric acid secretion research and antiulcer activity study design while keeping interpretation within the evidence and intended research-use scope.